



Published in final edited form as:

*AIMS Allergy Immunol.* 2017 ; 1(3): 143–163. doi:10.3934/Allergy.2017.3.143.

## “Toll-free” pathways for production of type I interferons

Ling Wang<sup>1,2</sup> and Shunbin Ning<sup>1,2,\*</sup>

<sup>1</sup>Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA

<sup>2</sup>Center of Excellence for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA

### Abstract

Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) are recognized by different cellular pathogen recognition receptors (PRRs), which are expressed on cell membrane or in the cytoplasm of cells of the innate immune system. Nucleic acids derived from pathogens or from certain cellular conditions represent a large category of PAMPs/DAMPs that trigger production of type I interferons (IFN-I) in addition to pro-inflammatory cytokines, by specifically binding to intracellular Toll-like receptors or cytosolic receptors. These cytosolic receptors, which are not related to TLRs and we call them “Toll-free” receptors, include the RNA-sensing RIG-I like receptors (RLRs), the DNA-sensing HIN200 family, and cGAS, amongst others. Viruses have evolved myriad strategies to evoke both host cellular and viral factors to evade IFN-I-mediated innate immune responses, to facilitate their infection, replication, and establishment of latency. This review outlines these “Toll-free” innate immune pathways and recent updates on their regulation, with focus on cellular and viral factors with enzyme activities.

### Keywords

PRR; cGAS; IFN-I; innate immunity

## 1. Introduction

Pathogen-associated molecular patterns (PAMPs) are usually derived from invading pathogens, and initiate rigorous innate immune responses after recognized by host germline-encoded pathogen recognition receptors (PRRs), which are expressed on cell membrane or in the cytoplasm of cells in the innate immune system. PRRs include the well-known transmembrane Toll-like receptors (TLRs), and an increasing pool of Toll-unrelated receptors (so we call them “Toll-free” receptors hereafter) that include retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), Caterpillar-like receptors (CLRs), the

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)

\*Correspondence: nings1@etsu.edu; Tel: +423-439-8063; Fax: +423-439-7010.

### Conflict of Interest

The authors declare that they have no competing interests in this paper.

HIN200/PYHIN family of nuclear antigens, cGMP-AMP synthase (cGAS), DNA-dependent activator of IRFs (DAI) [1], DDX9, DDX36 [2], DDX41 [3,4], RNA polymerase III [5], Ku70 [6], MRE11 [7], Sox2 [8], LRRFIP1 [9], ISG56/IFIT1 [10] and OASs [11], amongst others [12–15]. Intracellular PRRs, including endosomal TLRs, are able to recognize nucleic acids to trigger signal cascades for the activation of NF $\kappa$ B and specific interferon regulatory factors (IRFs) leading to production of type I interferons (IFN-I) [15]. Among these “Toll-free” receptors, RLRs and cGAS play non-redundant roles in the recognition of cytosolic RNAs and DNAs respectively, and they govern intracellular IFN-I-mediated innate immune responses. The involvement of other cytosolic “Toll-free” sensing pathways in IFN-I-mediated innate immunity is controversial due to the lack of solid evidence of genetic studies [16]. Importantly, recent studies have shown that the IFN-I signaling pathway plays a dual role in chronic viral infections. At the early stage of infection, it has a potent antiviral activity; however, at late stages, a low level of prolonged IFN-I response facilitates the establishment and maintenance of persistent infection [17–22].

Except PAMPs, host damage-associated molecular patterns (DAMPs), such as self-nucleic acids, heat-shock proteins and HMGB1, are also recognized by PRRs [13]. Self-DNA can be accumulated in the cytoplasm in mammalian cells under stress and specific physiological conditions, including but not limited to apoptosis, DNA damage, and spontaneous aging/senescence. [14,23,24]. Reactive oxygen species (ROS) produced from damaged mitochondria are one of the major cause of DNA damage, especially those with double-strand breaks, apart from other severe effects such as cell-cycle arrest, senescence and cell death [25–29]. Accumulation of damaged DNA fragments is able to activate cGAS- or RIG-I-mediated aberrant production of persistent IFN-I and AIM2-mediated inflammatory responses, causing autoimmune diseases and cancerogenesis [16,30–35]. Persistent IFN-I production also triggers chronic immune activation, and ultimately results in immune exhaustion and senescence, in the setting of persistent infection by viruses such as HIV and HCV [19,36,37].

Furthermore, there is substantial evidence showing that prolonged IFN-I signaling has important roles in regulating T cell responses in both direct and indirect manners, either promoting or inhibiting T cell activation, proliferation, differentiation and survival, and thus serves as a bridge that links innate and adaptive immune responses [19,20,21,38,39,40]. For example, CD4<sup>+</sup> T cells derived from HIV<sup>+</sup> subjects display an anergic phenotype, and a recent report has shown that engagement of TLR7 in HIV-infected CD4<sup>+</sup> T cells induces anergy/unresponsiveness, accounting for the impaired T cell function by chronic HIV infection [41].

In essence, IFN-I production has to be finely tuned to ensure appropriate mounting of antiviral and anti-tumor immunity and to maintain cellular homeostasis. We outline the “Toll-free” pathways triggering IFN-I production in this review, highlighting cGAS, HIN200, and RLRs, and recent updates on their regulation by cellular and viral factors with enzymatic activities.

## 2. “Toll-free” Nucleic Acid-Sensing Innate Immune Pathways

### 2.1. cGAS-STING cytosolic dsDNA-sensing pathway

2cGMP-AMP synthase (cGAS) synthesizes 2'3'-GMP-AMP (cGAMP) from ATP and GTP after binding to double-stranded DNA (dsDNA), and is the primary indispensable cytosolic sensor for both exogenous and endogenous dsDNA molecules, which, with the sizes of as short as 20 bp, are recognizable by high concentrations of cGAS or, with long sizes with bounded protein, recognizable by lower concentrations of cGAS [42]. In conjunct with ER-anchored IFN-inducible stimulator of interferon genes (STING, also called MITA, ERIS, MYPR) that functions as an adaptor to bind to cGAMP, cGAS-STING-mediated pathway plays a key role in innate immune responses against a large spectrum of DNA viruses (HSV1, vaccinia virus, adenovirus, KSHV, etc.), retroviruses (HIV1, HIV2, etc.) that produce pro-integrating DNA molecules, as well as bacteria (*Mycobacteria*, *Legionella*, *Listeria*, etc.) (Figure 1). In addition to viral infection, chemotherapeutic agents such as cisplatin, etoposide, and chitosan, induce oxidative DNA damage that promotes self-DNA leakage from the nucleus and mitochondrion, and therefore trigger cGAS-STING-mediated antitumor immune response (Figure 1) [28]. dsDNA molecules derived from retrotransposons such as short interspersed nuclear elements (SINEs) and Alu elements, can also function as ligands for cGAS. Approximately half of the mammalian genomes consist of retrotransposons [43].

Binding of cGAMP to two STING protomers results in translocation of STING from the ER compartment to perinuclear autophagy-like vesicles, where TBK1 is autophosphorylated and recruited to STING, allowing STING to be phosphorylated at Ser366, which is in an evolutionary conserved serine cluster shared with MAVS, TRIF, and IRF3 so that they all are also activated through similar phosphorylation-dependent mechanism [44]. Phosphorylated STING further recruits IRF3, resulting in its phosphorylation and activation by TBK1. cGAMP can be transferred to adjacent non-infected cells to spread antiviral activity, by diffusion or by being packed into viral particles, and therefore cGAS-STING can mount unique regional immune response [28].

STING itself is a receptor for bacterial cyclic dinucleotides (CDN) and their binding activates IFN-I responses in mice but not in humans (Figure 1). Binding of CDN to STING dimers causes the relief of STING autoinhibition, which allows STING to be ubiquitinated with K27 chains by the ER-anchored E3 ligases AMFR, further leading to the recruitment of TBK1 for IRF3 activation [45].

### 2.2. HIN200-mediated cytosolic dsDNA-sensing pathways

Except cGAS, two other important receptors for cytosolic dsDNA, AIM2 and IFI16, belong to the HIN200/PYHIN family that includes 4 members in humans: AIM2 (PYHIN4), IFI16 (PYHIN2), IFIX (PYHIN1), and MNDA (PYHIN3). The members are hematopoietic interferon-inducible nuclear antigens with 200 amino acid repeats and an N-terminal PYHIN (Pyrin and HIN) domain (except p202 in mice). Upon binding to DNA, both AIM2 and IFI16 trigger signal transduction to activate caspase 1 inflammasome leading to cleavage of pro-IL1 $\beta$  and pro-IL18 into mature bioactive IL1 $\beta$  and IL18 via the CARD-containing

adaptor ASC (CARD5) [46]. IFI16 preferentially recognizes longer naked DNA (>150 bp), and also triggers IFN-I responses via STING, in addition to its ability to induce caspase 1 inflammasome. AIM2 also triggers signal to caspase3-dependent apoptosis (Figure 2). Like cGAS, IFI16 and AIM2 bind to DNA independent of the DNA sequence [46].

Infection of a DNA virus activates both cGAS and IFI16 in the cytoplasm. However, recent studies support that DNA viral genome initiates IFI16-mediated immune response in the nucleus, where episomal genomes of almost all DNA viruses reside and replicate [47]. At the same time, viral infection (such as herpesviruses) imposes cellular stress that triggers mitochondrial DNA damage and release to activate cGAS-STING pathway [48]. Of special interest, Epstein-Barr Virus (EBV) latent infection, which is associated with various malignancies, constitutively induces IFI16-ASC-caspase 1 inflammasome that may represent a chronic inflammatory microenvironment for EBV-mediated oncogenesis [49].

Single-stranded DNA (ssDNA) derived from retroviral genome reverse transcription or from DNA replication (named Y-form DNA) potently stimulates IFN-I responses depending on cGAS or IFI16; whereas the RNA:DNA intermediate derived from reverse transcription prior to host genomic integration is detected by TLR9 and cGAS [50].

The other two HIN200 family members, IFIX and MNDA, are less studied but existing evidence has shown that they are involved in regulation of IFN signaling in cancers. IFIX promotes ubiquitination-mediated degradation of MDM2, leading to p53 stabilization, and stimulates maspin expression by promoting ubiquitination-mediated degradation of HDAC1, leading to impaired invasion activity of cancer cells.

### 2.3. RLR cytosolic RNA-sensing pathways

RLRs include RIG-I (DDX58), MDA5 (IFIH1), and LGP2, all of which contain a central DEAD box helicase/ATPase domain and a C-terminal regulatory domain (CTD); the latter (CTD) is essential for RNA binding. RIG-I and MDA5 each contains 2 CARD domains, and both signal through the mitochondrial CARD-containing antiviral signaling adaptor MAVS (also called VISA, IPS1, or CARDIF) that is located on mitochondrial membrane. RIG-I recognizes dsRNA synthesized from AT-rich dsDNA derived from DNA viruses (EBV, HSV1) and bacteria [5], and recognizes 5'-ppp ssRNA derived from the RNA viruses NDV, VSV, Sendai virus, influenza A virus and JEV; while MDA5 recognizes >300 bp long dsRNA such as poly (I:C) and RNA from EMCV and paramyxovirus (Figure 3) [51]. Solid evidence have shown that STING is also involved in RIG-I signaling, and interacts with MAVS in a complex that is stabilized in response to RNA virus infection, potentiating RIG-I-mediated antiviral responses (Figure 3) [51]. In the absence of ligand challenges, RIG-I and MDA5 are inactive due to phosphorylation at specific Thr and Ser residues (Ser8 and Thr170 of RIG-I, and Ser88 of MDA5), which is mediated by casein kinase II (CKII) and protein kinase C (PKC)- $\alpha/\beta$  respectively for RIG-I and by RIOK3 for MDA5. Activation of RIG-I and MDA5 requires their dephosphorylation by PP1 $\alpha/\gamma$ , ubiquitination, and ATP-dependent conformational changes leading to their multimerization upon binding to RNA. The other member, LGP2, can recognize RNA but lacks CARD domains, and results from knockout mice have shown that LGP2 is in fact a positive regulator of RIG-I/MDA5

signaling [52]. Different from TLRs that are restrictedly expressed in immune cells, epithelial cells and synovial fibroblasts, RLRs are expressed in most cell types.

#### 2.4. Other “Toll-free” cytosolic innate sensing pathways for IFN-I production

An increasing pool of individual cytosolic DNA and RNA sensors have been identified. Almost all these sensors trigger IFN-I production [13], except OASs that recognize dsRNA leading to RNA degradation by RNase L, and Sox2 that recognizes dsDNA triggering NF $\kappa$ B/API-mediated inflammation via activating the kinase complex TAK1-TAB2 (Figure 4) [8]. The adaptor STING converges different DNA sensing pathways for IRF3 activation leading to IFN-I production [53].

### 3. Evasion of “Toll-free” Innate Signaling Pathways

Innate sensing pathways are circumvented by numerous viral and cellular negative regulators (Figures 5 and 6). For example, Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded ORF52 and its homologs in other gammaherpesviruses (EBV, MHV68 and Rhesus monkey Rhadinovirus) inhibit cGAS activity to facilitate virus progeny [54,55]; KSHV-encoded vIRF1 negatively regulates STING-TBK1 interaction [56], and vIRF4 inhibits IRF7 transcriptional activity [57]. Some dsDNA and ssDNA viruses express proteins, including HPV E7 and human adenovirus E1A oncoproteins, with the Leu-x-Cys-x-Glu (LxCxE) motif that is known to block the Rb tumor suppressor [58]. The LxCxE motif mediates their interaction with STING to block IFN-I immune responses. Since these proteins are frequently used to immortalize cell lines [59], cGAS-STING pathway in these immortalized cell lines is compromised [50].

Nevertheless, those regulators with enzyme activities, such as DNA and RNA editing enzymes, kinases and phosphatases, ubiquitin E3 ligases and deubiquitinases, and histone modification enzymes, are especially interesting in that these regulators are potentially targeted with enzyme inhibitors for clinical interventions. In regard to evasion of HIV infection, these interesting enzymes include the RNA editing enzyme APOBEC3G, the ubiquitin E3 ligases TRIM5 $\alpha$  and TRIM22, the exonucleases TREX1 and SAMHD1, and the GTPase Mx2, and they are all inducible by IFN-I. Tetherin (BST2), another IFN-inducible host restriction factor with broad antiviral activity (including HIV1), directly tethers virions for internalization, leading to endocytosis and subsequently degradation [60,61]. Apoptotic caspases have also been found to negatively regulate cGAS-STING pathway, although the precise mechanism remains unclear [24,62]. Of note, many PRRs themselves have enzymatic activity, including RLRs, cGAS, and DDXs, and some of their family members negatively regulate PRR signaling pathways; for example, DDX46 negatively regulates IFN-I responses by retaining antiviral mRNAs of TRAF3, TRAF6, and MAVS in the nucleus through eliminating their m<sup>6</sup>A modification [63].

Apart from protein regulators, miRNAs represent another interesting category of immune inhibitors with clinical potentials [64,65,66]. For example, miR-27 targets STING gene 3’UTR and represses its expression, resulting in impaired CCL22-mediated recruitment of Tregs in human papillomavirus (HPV)-positive tongue squamous cell carcinoma (TSCC) [67]. STING, in addition to MAVS and IRF3, is also targeted for downregulation by

miR-576-3p [68]. Hypoxia induces Tet1-dependent expression of miR-25/93 that targets NCOA3, a lysine acetyltransferase that epigenetically induces cGAS expression in cooperation with AP1, resulting in suppression of cGAS expression in hypoxic breast cancers [69].

### 3.1. Evasion of nucleic acid sensing pathways by AGS exonucleases

The family of AGS exonucleases, including AGS1-5, are RNases except AGS1 (TREX1) that functions as a DNase. However, our recent in vitro biochemical evidence have shown that AGS1 can in fact also act as an RNase, which specifically degrades ssRNA [70]. Attention is especially focused on AGS1 and AGS5 (SAMHD1) because of their roles in HIV1 infection. TREX1 is responsible for the degradation of self-DNA in the cytosol. In the absence of TREX1, viral infections including HIV1 infection cause accumulation of cytoplasmic DNA, which activates the cGAS-STING pathway leading to IFN-I production and eventually viral replication is inhibited. Deficiency of TREX1 also causes Aicardi-Goutieres syndrome, a childhood inflammatory disorder characterized by high endogenous levels of IFN-I resulting from activation of DNA sensors by excess endogenous DNA.

### 3.2. Evasion of RNA sensing pathways by RNA editing enzymes

The RNA editing enzymes in humans consist of the adenosine deaminases that act on RNA (ADARs, A-to-I) family and the cytidine deaminases (AID/APOBECs, C-to-U) family.

The double-stranded RNA (dsRNA) A-to-I adenosine deaminase acting on RNAs (ADARs) include ADAR1 (IFI4), ADAR2, and ADAR3. ADAR1 has two forms; the longer form p150 is IFN-inducible but the shorter form p110 is constitutively expressed, ADAR2 is constitutively expressed, and ADAR3 has no enzyme activity [71]. Bioinformatics analysis has indicated that only limited sites in human transcriptome are potentially edited by ADARs; however, it is estimated approximately 20% of the human miRNA precursors are subject to ADAR editing, and in IFN-mediated antiviral responses, specific editable sites are increased [71]. Also, retrotransposons, which represent nearly half of the mammalian genomes, undergo extensive A-to-I editing [72]. ADAR1 also competes with RIG-I and MDA5 for dsRNA binding independently of its RNA editing activity and therefore suppresses IFN response upon RNA virus infection [73], and also negatively regulates OAS1- and PKR-mediated immune responses. Due to its ability to act on both cellular and viral dsRNAs, ADAR1 has broad roles in repressing antiviral immunity and preventing autoimmune diseases [74]. However, for some other viruses, including HCV and influenza virus, A-to-I editing of viral RNAs promotes antiviral activity [74].

Furthermore, ADARs have been shown to regulate DNA virus latent infection such as the oncogenic KSHV and EBV that encode ADAR-targeted RNA transcripts [74]. Site-specific A-to-I RNA editing of KSHV oncogenic K15 transcript (encodes miR-K10 and kaposin A) abrogates its transforming activity and promotes KSHV replication [75]. The EBV pre-miR-BART6 transcript undergo A-to-I editing that negatively regulates miR-BART6 biological functions [76]. A-to-I editing of viral transcripts at multiple sites may alter ORFs and results in aberrant expression of viral proteins.

The AID/APOBEC C-to-U family, including eleven members, can selectively act on either RNA or ssDNA [77]. Among these members, AID and APOBEC3 (APOBEC3A-H), are of great interest due to their antiviral activity against HBV, HCV, HIV, HTLV1, HPV, and herpesvirus infection [77]. The ssDNA deaminase AID, which is primarily expressed in germinal center (GC) B cells and is the only enzyme known to induce oncogenic mutations in the human genome, is induced upon infection with HCV or *Helicobacter pylori*, and is also induced by EBV LMP1 and HTLV1 Tax via NF $\kappa$ B in their latency. APOBEC3 deaminases are only expressed in mammals and inhibit retroviral infection by deaminating their DNA intermediates. For example, APOBEC3G defends viral infectivity factor 1 (VIF1)-deficient HIV infection; however, VIF1 causes APOBEC3G ubiquitination-dependent degradation. Similar to AID, APOBEC editing causes endogenous “off-target” DNA damage and genomic instability favoring cancer development, for example, in the setting of oncogenic HPV infection [77].

### 3.3. Evasion of type I IFN responses by protein kinases and phosphatases

Protein kinases usually activate PRR signaling by phosphorylating their components on specific sites. For example, the adaptors TRIF, MAVS and STING are phosphorylated at a serine site in a conserved motif pLxIS by TBK1 and IKK $\epsilon$  for the recruitment of IRF3 [44], and phosphorylation of IRF3 and IRF7 by IKKs or IRAK1 is prerequisite for their activation leading to IFN-I production. STING Ser366 phosphorylation by TBK1 is believed to be required for its activation [44], although another report showed that phosphorylation of this site by autophagy-related kinases ULK1 (ATG1) and ULK2 diminishes STING activity [78]. However, site-specific phosphorylation of some components may cause their inactivation. For example, phosphorylation of human cGAS S305 (S291 in mouse) by Akt potently inhibits cGAS enzymatic activity [79]. Phosphorylation of IRF3 Ser97 inhibits its activity but the phosphatase pTEN releases this inhibition to promote IRF3-mediated IFN-I antiviral responses [80]. Phosphorylation of RIG-I by IKK $\epsilon$  or PKC $\alpha/\beta$  negatively regulates its activity.

Recently, the roles of protein phosphatases in antiviral immune responses have emerged. PP1 and PP2A are positive regulators of Tat-dependent HIV1 transcription, and the <sup>35</sup>QVCF<sup>38</sup> motif of Tat directly interacts with PP1 [81]. PP1 also dephosphorylates the RNA sensors, MDA5 and RIG-I, and positively regulates their activity for IFN-I production in response to RNA virus infection [82,83]. Additionally, PP1 interacts with TRAF6, and promotes TRAF6-dependent innate immune responses [84].

In contrast, PP1 dephosphorylates Ebola virus VP30 and inhibits its transcription [85]. The measles virus V and the HBV X proteins can antagonize PP1 activity to facilitate their replication [83,86]. PP1 negatively regulates IRF3-mediated IFN-I production by inhibiting its phosphorylation at serines 396 and 385 [87], and together with GADD34, negatively regulates TLR-mediated immune response by inhibiting TAK1 serine 412 phosphorylation [88,89]. PP2A also deactivates IRF3 in cooperation with FBXO17 [90], and inhibits IFN-I signaling by inhibiting STAT1 phosphorylation and therefore contributes to HCV chronic infection [91]. More recently, we have identified PP1 as the first phosphatase that inactivates IRF7 by targeting its key phosphorylation sites and abrogates IRF7-mediated IFN-I

responses [92]. Further verification of this important finding in mouse models in vivo is necessary.

### 3.4. Evasion of “Toll-free” innate pathways by ubiquitinases and deubiquitinases

Besides phosphorylation/dephosphorylation, ubiquitination/deubiquitination represent another major epigenetic modification that is committed to fine regulation of myriad cellular functions. It seems all components in each PRR signaling pathway, including the receptor, the adaptor, TRAFs, and downstream IRFs, are regulated by ubiquitination (Figures 5 and 6) [93,94,95]. The involved cellular E3 ligases mainly include the TRAF, TRIM, and RNF families, and the cellular deubiquitinases mainly include the OTU and USP families [96,97]. For example, the deubiquitinases Gumbly (OTULIN), OTUD7b, and TNFAIP3 (A20) in the OUT family were shown to negatively regulate NF $\kappa$ B activation through different mechanisms in different biological contexts [98–104].

The ER-anchored RNF185 triggers K27-linked ubiquitination of cGAS promoting its activation [105]; AMFR-mediated K27-linked ubiquitination and TRIM32, TRM56, or MUL1-mediated K63-linked ubiquitination of STING are required for its activation [45,106,107,108], but HTLV1 Tax and HBV polymerase negatively regulate STING K63-linked ubiquitination, and the cellular E3 ligases RNF5 and TRIM30 $\alpha$  triggers STING K48-linked ubiquitination and degradation to alleviate cytosolic DNA sensing pathways [109–112]. RNF26 protects STING from RNF5-mediated degradation by targeting the same site (K150) for K11-linked ubiquitination, whereas promotes autophagy-mediated degradation of IRF3 [113]. USP21, a deubiquitinase, is recruited to STING after HSV1-stimulated phosphorylation via p38 and negatively regulates STING activity by hydrolyzing K27- and K63-linked ubiquitin chains of STING [114].

TRIM65 triggers K63-linked ubiquitination of MDA5 [115], and TRIM31 triggers K63-linked ubiquitination of downstream adaptor MAVS [116], both promoting RIG-I signaling pathway; whereas the membrane-anchored TRIM13 and TRIM59 negatively regulate MDA5-mediated IFN-I responses but promotes RIG-I activity through unclear mechanism that may involve additional cofactors [117]. TRIM4, TRIM25/RNF147, and Reul/RNF135/RIPLET E3 ligases promotes RIG-I K63-linked ubiquitination and activation [118–122]. In contrast, RNF122 and RNF125 target RIG-I for ubiquitination-mediated degradation [123,124].

TRIM21 targets IRF3 and DDX41, and TRIM26 and SENP2 target IRF3, for degradation, and TRIM21 also negatively regulates FADD-mediated antiviral immunity. TRIM35 targets IRF7 for degradation. We have shown that TRAF6 E3 ligase promotes IRF7 K63-linked ubiquitination that is required for EBV LMP1 activation of IRF7 [125]; however, A20, a member with both E3 ligase and deubiquitinase activities in the OTU family, inhibits LMP1-stimulated IRF7 activity by acting as a deubiquitinase [126].

In recent years, LUBAC-mediated linear polyubiquitination is coming into focus due to its emerging role in activation of NF $\kappa$ B in response to diverse signaling stimuli [127–132], including apoptotic and immune stimuli such as TNF $\alpha$  [133,134], IL1 $\beta$  [135], genotoxic stress [136], CD40 [137], Toll-like receptors (TLRs) [138], NOD2 [98], and NLRP3 [139].



LUBAC is a ternary ubiquitin ligase complex composed of HOIP (RNF31), HOIL1L (RNF54), and SHARPIN, and is constitutively formed under normal physiological conditions [133,134,140]. RNF31 is likely the central component of this complex [141]. LUBAC components are abundantly expressed in thymus and spleen, implying its potential role in lymphocytes [130]. Recent reports clearly show that LUBAC specifically activates the canonical NF $\kappa$ B pathway, but not the JNK pathway, by conjugating linear polyubiquitin chains onto NEMO and RIP1 [130,142]. However, LUBAC negatively regulates RIG-I-mediated innate immune responses by targeting RIG-I, TRIM25 and IRF3 for degradation [143,144], and by disrupting the TRAF3-MAVS complex [145]. We have recently shown that LUBAC-mediated linear ubiquitination is required for LMP1 activation of NF $\kappa$ B, but inhibits LMP1-stimulated IRF7 activity [146].

Compared with host cellular factors, virus-encoded factors are of greater interest in that they are virus-specific and easier to manipulate without affecting bypass cellular functions. Herpesvirus-encoded E3 ligases have been found to play crucial roles in evading innate immune responses for facilitating their infection and establishment of latent infection. For example, HSV1 ICP0 and HCMV pUL83 ubiquitin E3 ligases target IFI16 for proteasome-dependent degradation [147,148]. KSHV IE lytic transactivator RTA/ORF50 functions as a ubiquitin E3 ligase that targets IRF7 for degradation [149]. Herpesviruses also encode deubiquitinases, many of which have also been shown to evade innate immune responses. For example, EBV-encoded BPLF1 functions as a deubiquitinase that suppresses NF $\kappa$ B activation downstream of TLR signaling [150].

Ubiquitination-like modifications, especially sumoylation, have been shown to exert similar functions to ubiquitination in antiviral regulation. For example, TRIM38 stabilizes cGAS and STING by promoting their sumoylation [151], and TRIM28 is a SUMO E3 ligase that promotes IRF7 sumoylation and negatively regulates its activity [152]. These intriguing findings have advanced our current understanding of the novel functions of ubiquitination-like posttranslational modifications in signal transduction pathways [153,154].

#### 4. Closing Remarks

The increasing pool of cytosolic nucleic acid receptors have greatly advanced the study of IFN-I-mediated innate immune mechanisms, and may also shed light on type III IFNs-mediated responses that involve similar induction mechanisms to IFN-I. It is plausible that better understanding of innate immune pathways will benefit clinical applications for both antiviral infections and inflammation-related diseases including cancers. Recent research brings cGAS-STING pathway to the focus for potential treatments of cancers in that this pathway plays crucial roles in antitumor immunity and is aberrantly regulated in many cancers [28]. Future efforts may concentrate on the identification of viral and cellular regulators of these signaling pathways so as to design appropriate strategies such as cancer vaccines to evoke or interfere with their functions in different related disease settings, including cancers and autoimmune disorders.

## Acknowledgments

This work was supported by an NIH grant to SN (1R15DE027314) and in part by the NIH grant C06RR0306551. This publication is the result of work supported with resources and the use of facilities at the James H. Quillen Veterans Affairs Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or the United States Government.

## References

1. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature*. 2007; 448:501–505. [PubMed: 17618271]
2. Kim T, Pazhoor S, Bao M, et al. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. *Proc Natl Acad Sci USA*. 2010; 107:15181–15186. [PubMed: 20696886]
3. Parvatiyar K, Zhang Z, Teles RM, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. *Nat Immunol*. 2012; 13:1155–1161. [PubMed: 23142775]
4. Zhang Z, Yuan B, Bao M, et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. *Nat Immunol*. 2011; 12:959–965. [PubMed: 21892174]
5. Chiu YH, MacMillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. *Cell*. 2009; 138:576–591. [PubMed: 19631370]
6. Zhang X, Brann TW, Zhou M, et al. Ku70 is a novel cytosolic DNA sensor that induces type-III rather than type-I IFN. *J Immunol*. 2011; 186:4541–4545. [PubMed: 21398614]
7. Kondo T, Kobayashi J, Saitoh T, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. *Proc Natl Acad Sci USA*. 2013; 110:2969–2974. [PubMed: 23388631]
8. Xia P, Wang S, Ye B, et al. Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity against microbial infection. *Nat Immunol*. 2015; 16:366–375. [PubMed: 25729924]
9. Yang P, An H, Liu X, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. *Nat Immunol*. 2010; 11:487–494. [PubMed: 20453844]
10. Pichlmair A, Lassnig C, Eberle CA, et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. *Nat Immunol*. 2011; 12:624–630. [PubMed: 21642987]
11. Hornung V, Hartmann R, Ablasser A, et al. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. *Nat Rev Immunol*. 2014; 14:521–528. [PubMed: 25033909]
12. Ori D, Murase M, Kawai T. Cytosolic nucleic acid sensors and innate immune regulation. *Int Rev Immunol*. 2017; 36:74–88. [PubMed: 28333574]
13. Xia P, Wang S, Gao P, et al. DNA sensor cGAS-mediated immune recognition. *Protein Cell*. 2016; 7:777–791. [PubMed: 27696330]
14. Schlee M, Hartmann G. Discriminating self from non-self in nucleic acid sensing. *Nat Rev Immunol*. 2016; 16:566–580. [PubMed: 27455396]
15. Ning S, Pagano J, Barber G. IRF7: activation, regulation, modification, and function. *Genes Immun*. 2011; 12:399–414. [PubMed: 21490621]
16. Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. *Nat Immunol*. 2016; 17:1142–1149. [PubMed: 27648547]
17. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. *Science*. 2013; 340:202–207. [PubMed: 23580528]
18. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. *Science*. 2013; 340:207–211. [PubMed: 23580529]
19. Cha L, Berry CM, Nolan D, et al. Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. *Clin Trans Immunol*. 2014; 3:e10.

20. Catalfamo M, Wilhelm C, Tcheung L, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. *J Immunol.* 2011; 186:2106–2116. [PubMed: 21257970]
21. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. *Nat Rev Immunol.* 2015; 15:231–242. [PubMed: 25790790]
22. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. *Blood.* 2009; 113:58–65. [PubMed: 18849485]
23. Härtlova A, Erttmann SF, Raffi FAM, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. *Immunity.* 2015; 42:332–343. [PubMed: 25692705]
24. White MJ, McArthur K, Metcalf D, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. *Cell.* 2014; 159:1549–1562. [PubMed: 25525874]
25. Vilenchik MM, Knudson AG. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. *Proc Natl Acad Sci USA.* 2003; 100:12871–12876. [PubMed: 14566050]
26. de Galarreta MR, Lujambio A. DNA sensing in senescence. *Nat Cell Biol.* 2017; 19:1008–1009. [PubMed: 28855731]
27. Gluck S, Guey B, Gulen MF, et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. *Nat Cell Biol.* 2017; 19 In press.
28. Ng KW, Marshall EA, Bell JC, et al. cGAS-STING and cancer: dichotomous roles in tumor immunity and development. *Trends Immunol.* 2017 In press.
29. Yang H, Wang H, Ren J, et al. cGAS is essential for cellular senescence. *Proc Natl Acad Sci USA.* 2017; 114:E4612–E4620. [PubMed: 28533362]
30. Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. *Nat Med.* 2007; 13:543–551. [PubMed: 17479100]
31. Shibutani ST, Saitoh T, Nowag H, et al. Autophagy and autophagy-related proteins in the immune system. *Nat Immunol.* 2015; 16:1014–1024. [PubMed: 26382870]
32. Agod Z, Fekete T, Budai MM, et al. Regulation of type I interferon responses by mitochondria-derived reactive oxygen species in plasmacytoid dendritic cells. *Redox Biol.* 2017; 13:633–645. [PubMed: 28818792]
33. McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. *Nat Rev Immunol.* 2015; 15:87–103. [PubMed: 25614319]
34. Forster S. Interferon signatures in immune disorders and disease. *Immunol Cell Biol.* 2012; 90:520–527. [PubMed: 22491066]
35. Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. *Curr Opin Rheumatol.* 2012; 24:499–505. [PubMed: 22832823]
36. Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. *Nature.* 2014; 511:601–605. [PubMed: 25043006]
37. Mogensen T, Melchjorsen J, Larsen C, et al. Innate immune recognition and activation during HIV infection. *Retrovirology.* 2010; 7:54. [PubMed: 20569472]
38. Tough DF. Modulation of T-cell function by type I interferon. *Immunol Cell Biol.* 2012; 90:492–497. [PubMed: 22391814]
39. Zitvogel L, Galluzzi L, Kepp O, et al. Type I interferons in anticancer immunity. *Nat Rev Immunol.* 2015; 15:405–414. [PubMed: 26027717]
40. Gajewski TF, Corrales L. New perspectives on type I IFNs in cancer. *Cytokine Growth F R.* 2015; 26:175–178.
41. Dominguez-Villar M, Gautron AS, de Marcken M, et al. TLR7 induces anergy in human CD4+ T cells. *Nat Immunol.* 2015; 16:118–128. [PubMed: 25401424]
42. Andreeva L, Hiller B, Kostrewa D, et al. cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders. *Nature.* 2017 In press.
43. Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. *Nat Rev Genet.* 2009; 10:691–703. [PubMed: 19763152]

44. Liu S, Cai X, Wu J, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. *Science*. 2015; 347
45. Wang Q, Liu X, Cui Y, et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. *Immunity*. 2014; 41:919–933. [PubMed: 25526307]
46. Man SM, Karki R, Kanneganti TD. AIM2 inflammasome in infection, cancer, and autoimmunity: role in DNA sensing, inflammation, and innate immunity. *Eur J Immunol*. 2016; 46:269–280. [PubMed: 26626159]
47. Diner BA, Lum KK, Cristea IM. The emerging role of nuclear viral DNA sensors. *J Biol Chem*. 2015; 290:26412–26421. [PubMed: 26354430]
48. West AP, Khoury-Hanold W, Staron M, et al. Mitochondrial DNA stress primes the antiviral innate immune response. *Nature*. 2015; 520:553–557. [PubMed: 25642965]
49. Ansari MA, Singh VV, Dutta S, et al. Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells. *J Virol*. 2013; 87:8606–8623. [PubMed: 23720728]
50. Christensen MH, Paludan SR. Viral evasion of DNA-stimulated innate immune responses. *Cell Mol Immunol*. 2017; 14:4–13. [PubMed: 26972769]
51. Zevini A, Olganier D, Hiscott J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. *Trends Immunol*. 2017; 38:194–205. [PubMed: 28073693]
52. Satoh T, Kato H, Kumagai Y, et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. *Proc Natl Acad Sci USA*. 2010; 107:1512–1517. [PubMed: 20080593]
53. Kato K, Omura H, Ishitani R, et al. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. *Annu Rev Biochem*. 2017; 86:541–566. [PubMed: 28399655]
54. Wu JJ, Li W, Shao Y, et al. Inhibition of cGAS DNA sensing by a herpesvirus virion protein. *Cell Host Microbe*. 2015; 18:333–344. [PubMed: 26320998]
55. Li W, Avey D, Fu B, et al. Kaposi's sarcoma-associated herpesvirus inhibitor of cGAS (KicGAS), encoded by orf52, is an abundant tegument protein and is required for production of infectious progeny viruses. *J Virol*. 2016; 90:5329–5342. [PubMed: 27009954]
56. Ma Z, Jacobs SR, West JA, et al. Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. *Proc Natl Acad Sci USA*. 2015; 112:E4306–E4315. [PubMed: 26199418]
57. Hwang SW, Kim D, Jung JU, et al. KSHV-encoded viral interferon regulatory factor 4 (vIRF4) interacts with IRF7 and inhibits interferon alpha production. *Biochem Biophys Res Commun*. 2017; 486:700–705.
58. Lau L, Gray EE, Brunette RL, et al. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. *Science*. 2015; 350:568–571. [PubMed: 26405230]
59. de Souza RF, Iyer LM, Aravind L. Diversity and evolution of chromatin proteins encoded by DNA viruses. *BBA-Gene Regul Mech*. 2010; 1799:302–318.
60. Towers GJ, Noursadeghi M. Interactions between HIV-1 and the cell-autonomous innate immune system. *Cell Host Microbe*. 2014; 16:10–18. [PubMed: 25011104]
61. Sandstrom TS, Ranganath N, Angel JB. Impairment of the type I interferon response by HIV-1: potential targets for HIV eradication. *Cytokine Growth F R*. 2017 In press.
62. Rongvaux A, Jackson R, Harman CCD, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. *Cell*. 2014; 159:1563–1577. [PubMed: 25525875]
63. Zheng Q, Hou J, Zhou Y, et al. The RNA helicase DDX46 inhibits innate immunity by entrapping m6A-demethylated antiviral transcripts in the nucleus. *Nat Immunol*. 2017; 18:1094–1103. [PubMed: 28846086]
64. Boss IW, Renne R. Viral miRNAs and immune evasion. *BBA-Gene Regul Mech*. 2011; 1809:708–714.
65. Cullen BR. MicroRNAs as mediators of viral evasion of the immune system. *Nat Immunol*. 2013; 14:205–210. [PubMed: 23416678]
66. Wang L, Li G, Yao ZQ, et al. MicroRNA regulation of viral immunity, latency, and carcinogenesis of selected tumor viruses and HIV. *Rev Med Virol*. 2015; 25:320–341. [PubMed: 26258805]

67. Ding L, Huang XF, Dong GJ, et al. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal. *BBA-Mol Basis Dis.* 2015; 1852:2494–2503.
68. Yarbrough ML, Zhang K, Sakthivel R, et al. Primate-specific miR-576-3p sets host defense signaling threshold. *Nat Commun.* 2014; 5:4963–4963. [PubMed: 25232931]
69. Wu MZ, Cheng WC, Chen SF, et al. miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS. *Nat Cell Biol.* 2017; 19:1286–1296. [PubMed: 28920955]
70. Yuan F, Dutta T, Wang L, et al. Human DNA exonuclease TREX1 is also an exoribonuclease that acts on single-stranded RNA. *J Biol Chem.* 2015; 290:13344–13353. [PubMed: 25855793]
71. Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral dependent upon the virus. *Virology.* 2011; 411:180–193. [PubMed: 21211811]
72. Liddicoat BJ, Piskol R, Chalk AM, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. *Science.* 2015; 349:1115–1120. [PubMed: 26275108]
73. Yang S, Deng P, Zhu Z, et al. ADAR1 Limits RIG-I RNA detection and suppresses IFN production responding to viral and endogenous RNAs. *J Immunol.* 2014; 193:3436–3445. [PubMed: 25172485]
74. Wang Q, Li X, Qi R, et al. RNA Editing, ADAR1, and the innate immune response. *Genes.* 2017; 8:41.
75. Gandy SZ, Linnstaedt SD, Muralidhar S, et al. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. *J Virol.* 2007; 81:13544–13551. [PubMed: 17913828]
76. Iizasa H, Wulff BE, Alla NR, et al. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. *J Biol Chem.* 2010; 285:33358–33370. [PubMed: 20716523]
77. Rebhhandl S, Huemer M, Greil R, et al. AID/APOBEC deaminases and cancer. *Oncoscience.* 2015; 2:320–333. [PubMed: 26097867]
78. Konno H, Konno K, Barber GN. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. *Cell.* 2013; 155:688–698. [PubMed: 24119841]
79. Seo GJ, Yang A, Tan B, et al. Akt kinase-mediated checkpoint of cGAS DNA sensing pathway. *Cell Rep.* 2015; 13:440–449. [PubMed: 26440888]
80. Li S, Zhu M, Pan R, et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. *Nat Immunol.* 2016; 17:241–249. [PubMed: 26692175]
81. Nekhai S, Jerebtsova M, Jackson A, et al. Regulation of HIV-1 transcription by protein phosphatase 1. *Curr Hiv Res.* 2007; 5:3–9. [PubMed: 17266553]
82. Wies E, Wang MK, Maharaj NP, et al. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. *Immunity.* 2013; 38:437–449. [PubMed: 23499489]
83. Davis ME, Wang MK, Rennick LJ, et al. Antagonism of the phosphatase PP1 by the measles virus V protein is required for innate immune escape of MDA5. *Cell Host Microbe.* 2014; 16:19–30. [PubMed: 25011105]
84. Opaluch AM, Schneider M, Chiang CY, et al. Positive regulation of TRAF6-dependent innate immune responses by protein phosphatase PP1-gamma. *Plos One.* 2014; 9:e89284. [PubMed: 24586659]
85. Ilinykh PA, Tigabu B, Ivanov A, et al. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. *J Biol Chem.* 2014; 289:22723–22738. [PubMed: 24936058]
86. Cougot D, Allemand E, Rivière L, et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. *Sci Signal.* 2012; 5:ra1. [PubMed: 22215732]
87. Gu M, Zhang T, Lin W, et al. Protein phosphatase PP1 negatively regulates the Toll-like receptor- and RIG-I-like receptor-triggered production of type I interferon by inhibiting IRF3 phosphorylation at serines 396 and 385 in macrophage. *Sci Signal.* 2014 In press.


88. Gu M, Ouyang C, Lin W, et al. Phosphatase holoenzyme PP1/GADD34 negatively regulates TLR response by inhibiting TAK1 serine 412 phosphorylation. *J Immunol.* 2014; 192:2846–2856. [PubMed: 24534530]
89. Clavarino G, Claudio N, Dalet A, et al. Protein phosphatase 1 subunit Ppp1r15a/GADD34 regulates cytokine production in polyinosinic: polycytidylic acid-stimulated dendritic cells. *Proc Natl Acad Sci USA.* 2012 In press.
90. Peng D, Wang Z, Huang A, et al. A novel function of F-Box protein FBXO17 in negative regulation of type I IFN signaling by recruiting PP2A for IFN regulatory factor 3 deactivation. *J Immunol.* 2017; 198:808–819. [PubMed: 27956528]
91. Shanker V, Trincucci G, Heim HM, et al. Protein phosphatase 2A impairs IFN $\alpha$ -induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation. *J Viral Hepatitis.* 2013; 20:612–621.
92. Wang L, Zhao J, Ren J, et al. Protein phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity. *Eur J Immunol.* 2016; 46:2409–2419. [PubMed: 27469204]
93. Davis ME, Gack MU. Ubiquitination in the antiviral immune response. *Virology.* 2015:479–480. 52–65.
94. Lin D, Zhong B. Regulation of cellular innate antiviral signaling by ubiquitin modification. *Acta Biochim Biophys Sin (Shanghai).* 2015; 47:149–155. [PubMed: 25651846]
95. Heaton SM, Borg NA, Dixit VM. Ubiquitin in the activation and attenuation of innate antiviral immunity. *J Exp Med.* 2016; 213:1–13. [PubMed: 26712804]
96. Zhou Y, He C, Lin W, et al. Post-translational regulation of antiviral innate signaling. *Eur J Immunol.* 2017; 47:1414–1426. [PubMed: 28744851]
97. van Tol S, Hage A, Giraldo M, et al. The TRIMendous role of TRIMs in virus-host interactions. *Vaccines.* 2017; 5:23.
98. Damgaard RB, Nachbur U, Yabal M, et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. *Mol Cell.* 2012; 46:746–758. [PubMed: 22607974]
99. Keusekotten K, Elliott PR, Glockner L, et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. *Cell.* 2013; 153:1312–1326. [PubMed: 23746843]
100. Rivkin E, Almeida SM, Ceccarelli DF, et al. The linear ubiquitin-specific deubiquitinase gumbly regulates angiogenesis. *Nature.* 2013; 498:318–324. [PubMed: 23708998]
101. Takiuchi T, Nakagawa T, Tamiya H, et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. *Genes Cells.* 2014; 19:254–272. [PubMed: 24461064]
102. Tokunaga F, Nishimasu H, Ishitani R, et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF $\kappa$ B regulation. *Embo J.* 2012; 31:3856–3870. [PubMed: 23032187]
103. Hrdinka M, Fiil BK, Zucca M, et al. CYLD Limits Lys63- and Met1-Linked Ubiquitin at receptor complexes to regulate innate immune signaling. *Cell Rep.* 2016; 14:2846–2858. [PubMed: 26997266]
104. Damgaard RB, Walker JA, Marco-Casanova P, et al. The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. *Cell.* 2016; 166:1215–1230. [PubMed: 27523608]
105. Wang Q, Huang L, Hong Z, et al. The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. *Plos Pathog.* 2017; 13:e1006264. [PubMed: 28273161]
106. Ni G, Konno H, Barber GN. Ubiquitination of STING at lysine 224 controls IRF3 activation. *Sci Immunol.* 2017; 2 In Press.
107. Zhang J, Hu MM, Wang YY, et al. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. *J Biol Chem.* 2012; 287:28646–28655. [PubMed: 22745133]
108. Tsuchida T, Zou J, Saitoh T, et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. *Immunity.* 2010; 33:765–776. [PubMed: 21074459]

109. Wang J, Yang S, Liu L, et al. HTLV-1 Tax impairs K63-linked ubiquitination of STING to evade host innate immunity. *Virus Res.* 2017; 232:13–21. [PubMed: 28119118]
110. Liu Y, Li J, Chen J, et al. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. *J Virol.* 2015; 89:2287–2300. [PubMed: 25505063]
111. Zhong B, Zhang L, Lei C, et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. *Immunity.* 2009; 30:397–407. [PubMed: 19285439]
112. Wang Y, Lian Q, Yang B, et al. TRIM30 $\alpha$  is a negative-feedback regulator of the intracellular DNA and DNA virus-triggered response by targeting STING. *Plos Pathog.* 2015; 11:e1005012. [PubMed: 26114947]
113. Qin Y, Zhou MT, Hu MM, et al. RNF26 temporally regulates virus-triggered type I interferon induction by two distinct mechanisms. *Plos Pathog.* 2014; 10:e1004358. [PubMed: 25254379]
114. Chen Y, Wang L, Jin J, et al. p38 inhibition provides anti-DNA virus immunity by regulation of USP21 phosphorylation and STING activation. *J Exp Med.* 2017; 214:991–1010. [PubMed: 28254948]
115. Lang X, Tang T, Jin T, et al. TRIM65-catalized ubiquitination is essential for MDA5-mediated antiviral innate immunity. *J Exp Med.* 2017; 214:459–473. [PubMed: 28031478]
116. Liu B, Zhang M, Chu H, et al. The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the signaling adaptor MAVS through Lys63-linked polyubiquitination. *Nat Immunol.* 2017; 18:214–224. [PubMed: 27992402]
117. Narayan K, Waggoner L, Pham ST, et al. TRIM13 is a negative regulator of MDA5-mediated type I interferon production. *J Virol.* 2014; 88:10748–10757. [PubMed: 25008915]
118. Gao D, Yang YK, Wang RP, et al. REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-I. *Plos One.* 2009; 4:e5760. [PubMed: 19484123]
119. Oshiumi H, Matsumoto M, Hatakeyama S, et al. Riplet/RNF135, a RING-finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. *J Biol Chem.* 2009; 284:807–817. [PubMed: 19017631]
120. Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. *Nature.* 2007; 446:916–920. [PubMed: 17392790]
121. Jiang J, Li J, Fan W, et al. Robust Lys63-linked ubiquitination of RIG-I promotes cytokine eruption in early influenza B virus infection. *J Virol.* 2016; 90:6263–6275. [PubMed: 27122586]
122. Yan J, Li Q, Mao AP, et al. TRIM4 modulates type I interferon induction and cellular antiviral response by targeting RIG-I for K63-linked ubiquitination. *J Mol Cell Biol.* 2014; 6:154–163. [PubMed: 24755855]
123. Wang W, Jiang M, Liu S, et al. RNF122 suppresses antiviral type I interferon production by targeting RIG-I CARDs to mediate RIG-I degradation. *Proc Natl Acad Sci USA.* 2016; 113:9581–9586. [PubMed: 27506794]
124. Arimoto K, Takahashi H, Hishiki T, et al. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. *Proc Natl Acad Sci USA.* 2007; 104:7500–7505. [PubMed: 17460044]
125. Ning S, Campos AD, Darnay B, et al. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. *Mol Cell Biol.* 2008; 28:6536–6546. [PubMed: 18710948]
126. Ning S, Pagano J. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7. *J Virol.* 2010; 84:6130–6138. [PubMed: 20392859]
127. Iwai K, Fujita H, Sasaki Y. Linear ubiquitin chains: NF-kappaB signalling, cell death and beyond. *Nat Rev Mol Cell Bio.* 2014; 15:503–508. [PubMed: 25027653]
128. Rieser E, Cordier SM, Walczak H. Linear ubiquitination: a newly discovered regulator of cell signalling. *Trends Biochem Sci.* 2013; 38:94–102. [PubMed: 23333406]
129. Tokunaga F. Linear ubiquitination-mediated NF-kappaB regulation and its related disorders. *J Biochem.* 2013; 154:313–323. [PubMed: 23969028]
130. Tokunaga F, Iwai K. Linear ubiquitination: a novel NF-kappaB regulatory mechanism for inflammatory and immune responses by the LUBAC ubiquitin ligase complex. *Endocr J.* 2012; 59:641–652. [PubMed: 22673407]


131. Shimizu Y, Taraborrelli L, Walczak H. Linear ubiquitination in immunity. *Immunol Rev.* 2015; 266:190–207. [PubMed: 26085216]
132. Ikeda F. Linear ubiquitination signals in adaptive immune responses. *Immunol Rev.* 2015; 266:222–236. [PubMed: 26085218]
133. Ikeda F, Deribe YL, Skanland SS, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. *Nature.* 2011; 471:637–641. [PubMed: 21455181]
134. Tokunaga F, Nakagawa T, Nakahara M, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. *Nature.* 2011; 471:633–636. [PubMed: 21455180]
135. Tian Y, Zhang Y, Zhong B, et al. RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation. *J Biol Chem.* 2007; 282:16776–16782. [PubMed: 17449468]
136. Niu J, Shi Y, Iwai K, et al. LUBAC regulates NF-kappaB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. *EMBO J.* 2011; 30:3741–3753. [PubMed: 21811235]
137. Hostager BS, Kashiwada M, Colgan JD, et al. HOIL-1L interacting protein (HOIP) is essential for CD40 signaling. *Plos One.* 2011; 6:e23061. [PubMed: 21829693]
138. Zak DE, Schmitz F, Gold ES, et al. Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses. *Proc Natl Acad Sci USA.* 2011; 108:11536–11541. [PubMed: 21709223]
139. Rodgers MA, Bowman JW, Fujita H, et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. *J Exp Med.* 2014; 211:1333–1347. [PubMed: 24958845]
140. Kirisako T, Kamei K, Murata S, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. *EMBO J.* 2006; 25:4877–4887. [PubMed: 17006537]
141. Emmerich CH, Schmukle AC, Walczak H. The emerging role of linear ubiquitination in cell signaling. *Sci Signal.* 2011; 4:re5. [PubMed: 22375051]
142. Tokunaga F, Sakata Si, Saeki Y, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappa B activation. *Nat Cell Biol.* 2009; 11:123–132. [PubMed: 19136968]
143. Inn KS, Gack MU, Tokunaga F, et al. Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. *Mol Cell.* 2011; 41:354–365. [PubMed: 21292167]
144. Zhang M, Tian Y, Wang RP, et al. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. *Cell Res.* 2008; 18:1096–1104. [PubMed: 18711448]
145. Belgnaoui SM, Paz S, Samuel S, et al. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. *Cell Host Microbe.* 2012; 12:211–222. [PubMed: 22901541]
146. Wang L, Wang Y, Zhao J, et al. LUBAC modulates LMP1 activation of NFκB and IRF7. *J Virol.* 2017; 91:e1138–e1116.
147. Orzalli MH, DeLuca NA, Knipe DM. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. *Proc Natl Acad Sci USA.* 2012; 109:E3008–E3017. [PubMed: 23027953]
148. Li T, Chen J, Cristea IM. Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasion. *Cell Host Microbe.* 2013; 14:591–599. [PubMed: 24237704]
149. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteasome-mediated degradation. *Immunity.* 2005; 22:59–70. [PubMed: 15664159]
150. van Gent M, Braem SGE, de Jong A, et al. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with Toll-like receptor signaling. *Plos Pathog.* 2014; 10:e1003960. [PubMed: 24586164]
151. Hu MM, Yang Q, Xie XQ, et al. Sumoylation promotes the stability of the DNA sensor cGAS and the adaptor STING to regulate the kinetics of response to DNA virus. *Immunity.* 2016; 45:555–569. [PubMed: 27637147]




152. Liang Q, Deng H, Li X, et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN Regulatory Factor 7. *J Immunol.* 2011; 187:4754–4763. [PubMed: 21940674]
153. Yang WL, Zhang X, Lin HK. Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. *Oncogene.* 2010; 29:4493–4503. [PubMed: 20531303]
154. Yang Y, Kelly P, Schmitz R, et al. Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma. *Cancer Cell.* 2016; 29:494–507. [PubMed: 27070702]



**Figure 1.** cGAS-STING pathway senses cytosolic dsDNA. Cytosolic dsDNA derived from invading DNA viruses or retroviruses, or from self-genome under stress conditions (such as damaged mitochondrial DNA) binds to cGAS, leading the synthesis of cGAMP from ATP and GTP. cGAMP binds to STING dimers, resulting in STING phosphorylation and activation, further triggering downstream pathways for production of IFN-I and proinflammatory cytokines.




**Figure 2.** HIN200-mediated cytosolic dsDNA-sensing pathways. The dsDNA sensors AIM2 and IFI16 in the HIN200 family recognize long viral genome DNA in the cytoplasm, triggering caspase 3-mediated apoptosis and caspase 1-mediated inflammation. Recognition of dsDNA by IFI16 also triggers STING-mediated IRF3/7 activation and IFN-I production. While AIM2 activates caspases to trigger apoptosis and inflammation, mouse P202 inhibits AIM2-mediated pathways.



**Figure 3.** RLR-mediated RNA sensing pathways. RIG-I and MDA5 recognize different patterns of cytosolic RNA fragments derived from viruses, bacteria, or the host cell. STING interacts with RIG-I and MAVS in a complex that is stabilized upon RNA virus infection, facilitating the antiviral response. In addition, AT-rich dsDNA derived from bacteria or DNA viruses can be transcribed by RNA polymerase III into 5'-ppp dsRNA, which activates RIG-I-MAVS-TBK1-IRF3 pathway for IFN-I production.





**Figure 5.** Regulation of cGAS and STING by cellular and viral factors. Phosphorylation and ubiquitination are two major posttranslational modifications that regulate cGAS and STING protein stability and activity. Many viral factors, with or without enzyme activity, may also regulate their activities through other mechanisms, including direct interaction and employment of cellular factors as mediators.



**Figure 6.** Regulation of RLR signaling components. The receptors RIG-I and MDA5, the adaptor MAVS, and the downstream IRF3/7 are shown as examples in the RLR signaling pathways for their regulation by phosphorylation and ubiquitination at the posttranslational level. Many viral factors may also regulate their activities through other mechanisms.